Under the model, Asegua Therapeutics will supply hepatitis C treatments to the state Medicaid program and Department of Corrections in return for subscription-based payments. The state will pay a fixed dollar amount for unlimited access to the medication for five years. A finalized contract is expected June 1.
Asegua, the Gilead unit, will provide Louisiana with an authorized generic version of Epclusa, its top-selling hepatitis C treatment.
The pricing model aims to limit the amount the state pays for hepatitis C treatments, while also treating more individuals. The Louisiana Health Department hopes to treat more than 10,000 people by the end of 2020 and keep the total spending on hepatitis C drugs to $35 million or less, the collective amount Medicaid and the Louisiana Department of Corrections spent in fiscal year 2018.
The state began exploring a subscription-based model in response to budget concerns.
The Netflix-style model is being explored in other countries. Australia is working its way through a five-year agreement in which several drugmakers were paid a lump sum of $766 million for an unlimited volume of hepatitis C drugs. The deal was signed in 2015. Using the Netflix-style payment model for purchasing hepatitis C drugs is expected to lower patient costs in Australia by 85 percent.
More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy’s legal win expected to lower cost of opioid addiction treatment
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
